Glyburide, a common drug for type 2 diabetes (T2D) treatment, was the first identified NLRP3 inhibitor, though it does not inhibit NLRP1 or NLRC4-dependent IL-1β production [61]. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.